Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Penelope MacRae
The US regulator has slammed India’s Emcure Pharmaceuticals in a warning letter, accusing the company of slipshod investigation of tests showing microbial contamination and poor supervision, and has also sent a Form 483 containing eight observations to Dr Reddy’s.
Indian company Natco said it is looking to emerging markets, including Brazil and China, to grow earnings as its first-quarter net profit dropped by a fifth in its financial first quarter.
Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.
Aurobindo Pharma says its billion-dollar purchase of Sandoz’s US business is on track for completion “very soon” as it announced net first-quarter net profit that rocketed by nearly 40%, powered by strong US sales.
Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.
Bausch Health has settled its patent litigation with Teva over the Canadian firm’s ulcerative colitis medicine Apriso (mesalamine) 375mg extended-release capsules. The deal gives Teva the right to market a generic version of Apriso in the US in 2021, nine years before the patent on the drug expires.